- Home
- ESPR vs TDAC Comparison
ESPR vs TDAC Comparison
Compare ESPR & TDAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- TDAC
- Stock Information
- Founded
- ESPR 2008
- TDAC 2022
- Country
- ESPR United States
- TDAC United States
- Employees
- ESPR N/A
- TDAC N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- TDAC
- Sector
- ESPR Health Care
- TDAC
- Exchange
- ESPR Nasdaq
- TDAC NYSE
- Market Cap
- ESPR 208.1M
- TDAC 221.0M
- IPO Year
- ESPR 2013
- TDAC 2024
- Fundamental
- Price
- ESPR $1.07
- TDAC $10.27
- Analyst Decision
- ESPR Buy
- TDAC
- Analyst Count
- ESPR 7
- TDAC 0
- Target Price
- ESPR $5.93
- TDAC N/A
- AVG Volume (30 Days)
- ESPR 4.1M
- TDAC 18.6K
- Earning Date
- ESPR 08-11-2025
- TDAC 01-01-0001
- Dividend Yield
- ESPR N/A
- TDAC N/A
- EPS Growth
- ESPR N/A
- TDAC N/A
- EPS
- ESPR N/A
- TDAC 0.16
- Revenue
- ESPR $259,574,000.00
- TDAC N/A
- Revenue This Year
- ESPR $4.07
- TDAC N/A
- Revenue Next Year
- ESPR N/A
- TDAC N/A
- P/E Ratio
- ESPR N/A
- TDAC $160.48
- Revenue Growth
- ESPR 12.99
- TDAC N/A
- 52 Week Low
- ESPR $0.69
- TDAC $10.00
- 52 Week High
- ESPR $3.94
- TDAC $10.28
- Technical
- Relative Strength Index (RSI)
- ESPR 51.40
- TDAC N/A
- Support Level
- ESPR $1.13
- TDAC N/A
- Resistance Level
- ESPR $1.22
- TDAC N/A
- Average True Range (ATR)
- ESPR 0.08
- TDAC 0.00
- MACD
- ESPR 0.00
- TDAC 0.00
- Stochastic Oscillator
- ESPR 52.38
- TDAC 0.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About TDAC TRANSLATIONAL DEVELOPMENT ACQUISITI
Translational Development Acquisition Corp is a newly organized blank check company.